Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Product Acquisition/Disposal

Thumbnail
May 26, 2020

Merck joins Covid-19 pack with vaccine and antiviral deals

Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.

Thumbnail
December 09, 2019

J&J bets $750m that bermekimab has the X factor

Article image
Vantage logo
October 21, 2019

Bavarian’s chance to draw a line under oncology

The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.

Article image
Vantage logo
October 15, 2019

Admedus moves from one unlikely area to another

A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.

Article image
Vantage logo
August 19, 2019

Celgene's myelofibrosis win represents an expensive green light

Article image
Vantage logo
December 19, 2018

Apollo and Reshape play pass the parcel

Article image
Vantage logo
December 17, 2018

Lilly buys into ion channels – again

Article image
Vantage logo
November 01, 2018

Flipping for the win at Strongbridge Biopharma

Strongbridge's deal with Novo Nordisk over Macrilen tops up the former's cash pile and pays off debt just 10 months after the company licensed the project from…

Article image
Vantage logo
October 30, 2018

Astrazeneca bids the past farewell

Vantage logo
March 21, 2018

Amid mounting questions, Celgene keeps spending

Vantage logo
March 16, 2018

Snippet roundup: J&J shrinks, while Vernalis vanishes altogether

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2020 Evaluate Ltd.